title: N-acetylcysteine for the management of anemia and oxidative stress in hemodialysis patients.
abstract: OBJECTIVE
  To explore the efficacy of oral N-acetylcysteine (NAC) supplementation for anemia and oxidative stress in hemodialysis (HD) patients.
  
  
  METHODS
  Of the eligible patients (n = 325) in an outpatient HD unit, 49 received NAC 200 mg orally thrice a day during the first 3 months, while the other 276 patients not receiving NAC were observed.
  
  
  RESULTS
  During the 4-month study, 11 patients receiving NAC withdrew but had no severe adverse effects, while 49 patients not receiving NAC had negative confounding events. Thus only the data of the remaining patients, 38 taking NAC and 227 not taking NAC, were analyzed for efficacy. The demographic and laboratory data of both groups were similar at baseline. When the erythropoietin dosage was stable throughout, only the NAC group had a significant increase in hematocrit, accompanied with a decrease in plasma levels of 8-isoprostane and oxidized low-density lipoprotein. Analyzed as a nested case-control study, NAC supplementation was also found to be a significant predictor of positive outcomes in uremic anemia.
  
  
  CONCLUSIONS
  Oral NAC supplementation may be a promising therapy for uremic anemia and oxidative stress in HD patients.
authors.affiliation: Department of Internal Medicine, Far Eastern Memorial Hospital,Taipei, Taiwan.
authors.forename: Shih-Ping
authors.initials: SP
authors.lastname: Hsu
authors.forename: Chih-Kang
authors.initials: CK
authors.lastname: Chiang
authors.forename: Shao-Yu
authors.initials: SY
authors.lastname: Yang
authors.forename: Chiang-Ting
authors.initials: CT
authors.lastname: Chien
mesh_terms: D000111:Acetylcysteine / Q000009:adverse effects / Q000627:therapeutic use*; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000188:drug therapy*; D000975:Antioxidants / Q000009:adverse effects / Q000627:therapeutic use*; D016022:Case-Control Studies; D002712:Chlorides / Q000627:therapeutic use; D015237:Dinoprost / Q000031:analogs & derivatives / Q000097:blood; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D005290:Ferric Compounds / Q000627:therapeutic use; D006400:Hematocrit; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000628:therapy*; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis / Q000009:adverse effects*
chemical_list: D000975:Antioxidants; D002712:Chlorides; D005290:Ferric Compounds; D008077:Lipoproteins, LDL; D011994:Recombinant Proteins; C099252:oxidized low density lipoprotein; D004921:Erythropoietin; C075750:8-epi-prostaglandin F2alpha; D015237:Dinoprost; C024555:ferric chloride; D000111:Acetylcysteine